PT3342773T - Inibidores syk - Google Patents

Inibidores syk

Info

Publication number: PT3342773T
Authority: PT; Portugal
Prior art keywords: syk inhibitors; syk; inhibitors
Prior art date: 2013-12-23

Application number

PT181560343T

Other languages

English (en)

Original Assignee

Kronos Bio Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-23

Filing date

2014-12-22

Publication date

2021-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52350364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3342773(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-22 Application filed by Kronos Bio Inc filed Critical Kronos Bio Inc

2021-02-17 Publication of PT3342773T publication Critical patent/PT3342773T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Neurology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)

PT181560343T 2013-12-23 2014-12-22 Inibidores syk PT3342773T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201361920407P	2013-12-23	2013-12-23

Publications (1)

Publication Number	Publication Date
PT3342773T true PT3342773T (pt)	2021-02-17

Family

ID=52350364

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT181560343T PT3342773T (pt)	2013-12-23	2014-12-22	Inibidores syk
PT148276694T PT3087075T (pt)	2013-12-23	2014-12-22	Inibidores syk

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT148276694T PT3087075T (pt)	2013-12-23	2014-12-22	Inibidores syk

Country Status (44)

Country	Link
US (5)	US9968601B2 (pt)
EP (2)	EP3342773B9 (pt)
JP (3)	JP6243062B2 (pt)
KR (3)	KR20200098735A (pt)
CN (2)	CN107746405B (pt)
AP (1)	AP2016009274A0 (pt)
AR (1)	AR098912A1 (pt)
AU (3)	AU2014370010B2 (pt)
BR (1)	BR112016014643B1 (pt)
CA (1)	CA2875877C (pt)
CL (1)	CL2016001537A1 (pt)
CR (1)	CR20160287A (pt)
CU (1)	CU20160097A7 (pt)
CY (1)	CY1120104T1 (pt)
DK (2)	DK3087075T3 (pt)
DO (1)	DOP2016000140A (pt)
EA (2)	EA031131B1 (pt)
ES (2)	ES2851335T3 (pt)
GT (1)	GT201600123A (pt)
HK (1)	HK1251563A1 (pt)
HR (2)	HRP20180460T1 (pt)
HU (2)	HUE053815T2 (pt)
IL (1)	IL245846B (pt)
LT (1)	LT3087075T (pt)
MD (1)	MD4666C1 (pt)
ME (1)	ME03001B (pt)
MX (2)	MX371024B (pt)
MY (1)	MY199564A (pt)
NO (1)	NO3183247T3 (pt)
NZ (1)	NZ721175A (pt)
PE (1)	PE20160995A1 (pt)
PH (2)	PH12020551986A1 (pt)
PL (2)	PL3342773T3 (pt)
PT (2)	PT3342773T (pt)
RS (1)	RS57182B1 (pt)
SG (3)	SG10201707432SA (pt)
SI (2)	SI3342773T1 (pt)
SM (1)	SMT201800193T1 (pt)
SV (1)	SV2016005229A (pt)
TW (2)	TWI662037B (pt)
UA (2)	UA118463C2 (pt)
UY (1)	UY35898A (pt)
WO (1)	WO2015100217A1 (pt)
ZA (1)	ZA201800913B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2009325133B2 (en)	2008-12-08	2016-02-04	Gilead Connecticut, Inc.	Imidazopyrazine Syk inhibitors
NZ602362A (en)	2010-03-11	2014-11-28	Gilead Connecticut Inc	Imidazopyridines syk inhibitors
HK1222390A1 (zh)	2013-07-30	2017-06-30	吉利德康涅狄格公司	Syk抑制劑的多晶型
EP3027601B1 (en)	2013-07-31	2017-10-25	Gilead Sciences, Inc.	Syk inhibitors
DK3076976T3 (da)	2013-12-04	2020-12-07	Kronos Bio Inc	Fremgangsmåder til behandling af cancer
UY35898A (es) *	2013-12-23	2015-07-31	Gilead Sciences Inc	?compuestos inhibidores de syk y composiciones que los comprenden?.
EP3169366A1 (en)	2014-07-14	2017-05-24	Gilead Sciences, Inc.	Combinations for treating cancers
TW201617074A (zh)	2014-07-14	2016-05-16	吉李德科學股份有限公司	Ｓｙｋ（脾酪胺酸激酶）抑制劑
JP2018513173A (ja) *	2015-04-21	2018-05-24	ギリアードサイエンシーズ，インコーポレイテッド	Ｓｙｋ阻害剤を用いた慢性移植片対宿主病の処置
US20180207164A1 (en) *	2015-08-03	2018-07-26	Gilead Sciences, Inc.	Combination therapies for treating cancers
WO2017106564A1 (en) *	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
EP3512519A1 (en) *	2016-09-14	2019-07-24	Gilead Sciences, Inc.	Syk inhibitors
TW201822764A (zh) *	2016-09-14	2018-07-01	美商基利科學股份有限公司	Syk抑制劑
JOP20180040A1 (ar)	2017-04-20	2019-01-30	Gilead Sciences Inc	مثبطات pd-1/pd-l1
CA3073871A1 (en)	2017-08-25	2019-02-28	Gilead Sciences, Inc.	Polymorphs of syk inhibitors
SG11202002475TA (en)	2017-10-19	2020-04-29	Bayer Animal Health Gmbh	Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
IL300572A (en)	2018-02-13	2023-04-01	Gilead Sciences Inc	PD–1/PD–L1 inhibitors
TWI712412B (zh)	2018-04-19	2020-12-11	美商基利科學股份有限公司	Pd‐1/pd‐l1抑制劑
CN112118845B (zh)	2018-05-14	2023-06-13	吉利德科学公司	Mcl-1抑制剂
PT3820572T (pt)	2018-07-13	2023-11-10	Gilead Sciences Inc	Inibidores pd-1/pd-l1
CN110833549B (zh) *	2018-08-15	2023-05-02	广西梧州制药（集团）股份有限公司	吡唑并嘧啶衍生物在治疗慢性盆腔炎的用途
US11236085B2 (en)	2018-10-24	2022-02-01	Gilead Sciences, Inc.	PD-1/PD-L1 inhibitors
CN113950479A (zh)	2019-02-22	2022-01-18	克洛诺斯生物股份有限公司	作为syk抑制剂的缩合吡嗪的固体形式
EA202192575A1 (ru)	2019-03-21	2022-01-14	Онксео	Соединения dbait в сочетании с ингибиторами киназ для лечения рака
WO2021089791A1 (en)	2019-11-08	2021-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
WO2021244430A1 (en)	2020-06-01	2021-12-09	Nanjing Ruijie Pharma Co., Ltd.	Compounds and their uses as spleen tyrosine kinase inhibitors
WO2022026753A1 (en) *	2020-07-29	2022-02-03	University Of Kentucky Research Foundation	Gold(iii) compounds and cancer cell-selective modulation of mitochondrial respiration and metabolism
WO2022026757A1 (en) *	2020-07-29	2022-02-03	University Of Kentucky Research Foundation	Accelerating repair of mucosal injury using gold(iii) compounds
CN112939983A (zh) *	2021-02-01	2021-06-11	暨明医药科技（苏州）有限公司	一种SYK激酶抑制剂Lanraplenib的合成方法
CN113480543B (zh) *	2021-07-07	2022-05-17	无锡市第二人民医院	2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用
WO2024037910A1 (en) *	2022-08-17	2024-02-22	Institut National de la Santé et de la Recherche Médicale	Syk inhibitors for use in the treatment of cancer
WO2024102970A1 (en) *	2022-11-11	2024-05-16	Kronos Bio, Inc.	Compounds for modulating syk activity and e3 ubiquitin ligase activity
WO2024124063A1 (en) *	2022-12-09	2024-06-13	Kronos Bio, Inc.	Crystalline forms of lanraplenib and methods of making and using the same
CN118286149B (zh) *	2024-04-17	2024-12-24	湖南天华医药生物科技有限公司	一种治疗风湿骨痛的组合物及其制备方法及其应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US4326525A (en)	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US5364620A (en)	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
FR2607813B1 (fr)	1986-12-05	1989-03-31	Montpellier I Universite	Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
US5001139A (en)	1987-06-12	1991-03-19	American Cyanamid Company	Enchancers for the transdermal flux of nivadipine
US4992445A (en)	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US4902514A (en)	1988-07-21	1990-02-20	Alza Corporation	Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5137876A (en)	1990-10-12	1992-08-11	Merck & Co., Inc.	Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
DE4327027A1 (de)	1993-02-15	1994-08-18	Bayer Ag	Imidazoazine
DE4337611A1 (de)	1993-11-04	1995-05-11	Boehringer Ingelheim Kg	Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4337609A1 (de)	1993-11-04	1995-05-11	Boehringer Ingelheim Kg	Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
FR2711993B1 (fr)	1993-11-05	1995-12-01	Rhone Poulenc Rorer Sa	Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
US6334997B1 (en)	1994-03-25	2002-01-01	Isotechnika, Inc.	Method of using deuterated calcium channel blockers
JP3696884B2 (ja)	1994-03-25	2005-09-21	アイソテクニカ、インコーポレーテッド	ジュウテリウム化による薬物の効能の増強
FR2723373B1 (fr)	1994-08-02	1996-09-13	Rhone Poulenc Rorer Sa	Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent
AU5348396A (en)	1995-05-01	1996-11-21	Fujisawa Pharmaceutical Co., Ltd.	Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
US5593997A (en)	1995-05-23	1997-01-14	Pfizer Inc.	4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
SE9704404D0 (sv)	1997-11-28	1997-11-28	Astra Ab	New compounds
AU762839B2 (en)	1999-01-25	2003-07-03	Apoxis Sa	Baff, related blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
DE19948434A1 (de)	1999-10-08	2001-06-07	Gruenenthal Gmbh	Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
DE60028754T2 (de)	1999-11-12	2007-05-31	Abbott Laboratories, Abbott Park	Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
KR100558239B1 (ko)	1999-12-23	2006-03-10	화이자 프로덕츠 인크.	증가된 약물 농도를 제공하는 제약학적 조성물
JP2001302667A (ja)	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
GB0018473D0 (en)	2000-07-27	2000-09-13	Merck Sharp & Dohme	Therapeutic agents
DE10050663A1 (de)	2000-10-13	2002-04-18	Gruenenthal Gmbh	Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
WO2002060492A1 (en) *	2001-01-30	2002-08-08	Cytopia Pty Ltd	Methods of inhibiting kinases
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
WO2002076985A1 (en)	2001-03-23	2002-10-03	Smithkline Beecham Corporation	Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
AU2003219690A1 (en)	2002-02-19	2003-09-09	Pharmacia And Upjohn Company	Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
AU2003221731B2 (en)	2002-04-19	2010-04-15	Cgi Pharmaceuticals, Inc.	Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof
US20040072081A1 (en)	2002-05-14	2004-04-15	Coleman Thomas P.	Methods for etching photolithographic reticles
WO2003095447A1 (en)	2002-05-14	2003-11-20	Xenova Limited	Process for the preparation of a hydrate of an anthranilic acid derivative
WO2004022562A1 (en)	2002-09-09	2004-03-18	Cellular Genomics, Inc.	6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
MXPA05003058A (es)	2002-09-19	2005-05-27	Schering Corp	Nuevas imidazopiridinas como inhibidores de cinasa dependientes de ciclina.
CN1694706A (zh)	2002-09-23	2005-11-09	先灵公司	用作依赖细胞周期蛋白的激酶抑制剂的新的咪唑并吡嗪
WO2004026877A1 (en)	2002-09-23	2004-04-01	Schering Corporation	Imidazopyrazines as cyclin dependent kinase inhibitors
US7189723B2 (en)	2003-02-10	2007-03-13	Cgi Pharmaceuticals, Inc.	Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7186832B2 (en)	2003-02-20	2007-03-06	Sugen Inc.	Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7157460B2 (en)	2003-02-20	2007-01-02	Sugen Inc.	Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2005014599A1 (en)	2003-06-04	2005-02-17	Cellular Genomics, Inc.	Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US20060183746A1 (en)	2003-06-04	2006-08-17	Currie Kevin S	Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en)	2003-06-30	2005-01-20	Cellular Genomics, Inc.	Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005019220A2 (en)	2003-08-11	2005-03-03	Cellular Genomics Inc.	Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
WO2005047290A2 (en)	2003-11-11	2005-05-26	Cellular Genomics Inc.	Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
US7973161B2 (en)	2003-11-13	2011-07-05	Abbott Laboratories	Apoptosis promoters
WO2005085252A1 (en)	2004-03-04	2005-09-15	Biofocus Discovery Limited	Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
CN1968684A (zh)	2004-06-17	2007-05-23	森林实验室公司	美金刚的调释制剂
WO2006044687A2 (en)	2004-10-15	2006-04-27	Takeda San Diego, Inc.	Kinase inhibitors
CN101124227A (zh)	2004-11-10	2008-02-13	Cgi制药有限公司	可用作激酶活性调节剂的咪唑并[1,2-a]吡嗪-8-基胺
JP2008519843A (ja)	2004-11-10	2008-06-12	シージーアイファーマスーティカルインコーポレーテッド	特定のイミダゾ［１，２−ａ］ビラジン−８−イラミンズ、その生成方法及びそれに関する使用方法
PT1888550E (pt)	2005-05-12	2014-09-03	Abbvie Bahamas Ltd	Promotores de apoptose
KR20080074963A (ko)	2005-11-10	2008-08-13	쉐링 코포레이션	단백질 키나제 억제제로서의 이미다조피라진
AU2007291190A1 (en)	2006-08-30	2008-03-06	Cellzome Limited	Triazole derivatives as kinase inhibitors
PE20080839A1 (es)	2006-09-11	2008-08-23	Cgi Pharmaceuticals Inc	Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
CL2008002793A1 (es)	2007-09-20	2009-09-04	Cgi Pharmaceuticals Inc	Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
MX2010005718A (es)	2007-11-28	2010-08-10	Irx Therapeutics Inc	Metodo para incrementar el efecto inmunologico.
CN101952283B (zh)	2007-12-14	2013-04-17	霍夫曼-拉罗奇有限公司	咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
AR075257A1 (es)	2008-02-01	2011-03-23	Hexima Ltd	Sistema de proteccion de plantas contra la infeccion por agentes patogenos
TW200938542A (en)	2008-02-01	2009-09-16	Irm Llc	Compounds and compositions as kinase inhibitors
WO2009102468A1 (en)	2008-02-13	2009-08-20	Cgi Pharmaceuticals, Inc.	6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
EP2241151B1 (en)	2008-02-15	2016-12-14	Telefonaktiebolaget LM Ericsson (publ)	Accessing a communications channel
EP2280711A1 (en)	2008-03-07	2011-02-09	Pfizer Inc.	Methods, dosage forms, and kits for administering ziprasidone without food
WO2009137596A1 (en)	2008-05-06	2009-11-12	Cgi Pharmaceuticals, Inc.	Substituted amides, method of making, and use as btk inhibitors
WO2009156284A1 (en)	2008-06-24	2009-12-30	F. Hoffmann-La Roche Ag	Novel substituted pyridin-2-ones and pyridazin-3-ones
DK2300459T3 (da)	2008-07-02	2013-09-02	Hoffmann La Roche	Nye fenylpyrazinoner som kinasehæmmere
EP2307413B1 (en)	2008-07-15	2015-09-09	F. Hoffmann-La Roche AG	Novel phenyl-imidazopyridines and pyridazines
TWI453207B (zh)	2008-09-08	2014-09-21	Signal Pharm Llc	胺基三唑并吡啶，其組合物及使用其之治療方法
US8450321B2 (en)	2008-12-08	2013-05-28	Gilead Connecticut, Inc.	6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
KR20170066685A (ko)	2008-12-08	2017-06-14	질레드 코네티컷 인코포레이티드	이미다조피라진 ｓｙｋ 억제제
AU2009325133B2 (en)	2008-12-08	2016-02-04	Gilead Connecticut, Inc.	Imidazopyrazine Syk inhibitors
US8362013B2 (en)	2009-04-30	2013-01-29	Abbvie Inc.	Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en)	2009-05-26	2013-10-01	Abbvie Inc.	Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
JP5714600B2 (ja)	2009-12-18	2015-05-07	フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａＮｅｄｅｒｌａｎｄＨｏｌｄｉｎｇＢ．Ｖ．	共加工された錠用賦形剤混合物、その調製及び使用
DK2516434T3 (en)	2009-12-23	2015-08-31	Takeda Pharmaceutical	FUSED HETEROAROMATIC PYRROLIDINONS AS SICK INHIBITORS
NZ602362A (en)	2010-03-11	2014-11-28	Gilead Connecticut Inc	Imidazopyridines syk inhibitors
RU2628560C2 (ru)	2010-11-23	2017-08-18	Эббви Инк.	Соли и кристаллические формы индуцирующего апоптоз агента
JPWO2012147832A1 (ja)	2011-04-27	2014-07-28	第一三共株式会社	フェニルピロール誘導体の結晶
WO2013188856A1 (en) *	2012-06-14	2013-12-19	Gilead Connecticut, Inc.	Imidazopyrazine syk inhibitors
EP2884980A1 (en)	2012-08-14	2015-06-24	Gilead Calistoga LLC	Combination therapies for treating cancer
US20140148430A1 (en)	2012-11-26	2014-05-29	Gilead Connecticut, Inc.	Imidazopyridines syk inhibitors
HK1222390A1 (zh)	2013-07-30	2017-06-30	吉利德康涅狄格公司	Syk抑制劑的多晶型
NZ715745A (en)	2013-07-30	2017-06-30	Gilead Connecticut Inc	Formulation of syk inhibitors
EP3027601B1 (en)	2013-07-31	2017-10-25	Gilead Sciences, Inc.	Syk inhibitors
DK3076976T3 (da)	2013-12-04	2020-12-07	Kronos Bio Inc	Fremgangsmåder til behandling af cancer
US9440991B2 (en)	2013-12-23	2016-09-13	Gilead Sciences, Inc.	Synthesis of an antiviral compound
US9290505B2 (en)	2013-12-23	2016-03-22	Gilead Sciences, Inc.	Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (es)	2013-12-23	2015-07-31	Gilead Sciences Inc	?compuestos inhibidores de syk y composiciones que los comprenden?.
EP3169366A1 (en)	2014-07-14	2017-05-24	Gilead Sciences, Inc.	Combinations for treating cancers
TW201617074A (zh)	2014-07-14	2016-05-16	吉李德科學股份有限公司	Ｓｙｋ（脾酪胺酸激酶）抑制劑
TW201639573A (zh)	2015-02-03	2016-11-16	吉李德科學股份有限公司	有關治療癌症之合併治療
JP2018513173A (ja)	2015-04-21	2018-05-24	ギリアードサイエンシーズ，インコーポレイテッド	Ｓｙｋ阻害剤を用いた慢性移植片対宿主病の処置
TW201822764A (zh)	2016-09-14	2018-07-01	美商基利科學股份有限公司	Syk抑制劑
EP3512519A1 (en)	2016-09-14	2019-07-24	Gilead Sciences, Inc.	Syk inhibitors
CN113950479A (zh)	2019-02-22	2022-01-18	克洛诺斯生物股份有限公司	作为syk抑制剂的缩合吡嗪的固体形式

2014
- 2014-12-19 UY UY0001035898A patent/UY35898A/es not_active Application Discontinuation
- 2014-12-19 TW TW103144664A patent/TWI662037B/zh active
- 2014-12-19 TW TW108110295A patent/TWI735853B/zh active
- 2014-12-22 ES ES18156034T patent/ES2851335T3/es active Active
- 2014-12-22 KR KR1020207023431A patent/KR20200098735A/ko not_active Ceased
- 2014-12-22 HU HUE18156034A patent/HUE053815T2/hu unknown
- 2014-12-22 RS RS20180332A patent/RS57182B1/sr unknown
- 2014-12-22 MX MX2016008456A patent/MX371024B/es active IP Right Grant
- 2014-12-22 BR BR112016014643-3A patent/BR112016014643B1/pt active IP Right Grant
- 2014-12-22 AP AP2016009274A patent/AP2016009274A0/en unknown
- 2014-12-22 EA EA201690989A patent/EA031131B1/ru unknown
- 2014-12-22 SG SG10201707432SA patent/SG10201707432SA/en unknown
- 2014-12-22 EP EP18156034.3A patent/EP3342773B9/en active Active
- 2014-12-22 PT PT181560343T patent/PT3342773T/pt unknown
- 2014-12-22 DK DK14827669.4T patent/DK3087075T3/en active
- 2014-12-22 CN CN201711091018.7A patent/CN107746405B/zh active Active
- 2014-12-22 WO PCT/US2014/071842 patent/WO2015100217A1/en active Application Filing
- 2014-12-22 MD MDA20160078A patent/MD4666C1/ro active IP Right Grant
- 2014-12-22 PH PH1/2020/551986A patent/PH12020551986A1/en unknown
- 2014-12-22 MY MYPI2016702306A patent/MY199564A/en unknown
- 2014-12-22 PL PL18156034T patent/PL3342773T3/pl unknown
- 2014-12-22 HU HUE14827669A patent/HUE037662T2/hu unknown
- 2014-12-22 PE PE2016000814A patent/PE20160995A1/es active IP Right Grant
- 2014-12-22 CR CR20160287A patent/CR20160287A/es unknown
- 2014-12-22 PT PT148276694T patent/PT3087075T/pt unknown
- 2014-12-22 AR ARP140104854A patent/AR098912A1/es unknown
- 2014-12-22 KR KR1020167019931A patent/KR101925859B1/ko active Active
- 2014-12-22 CA CA2875877A patent/CA2875877C/en active Active
- 2014-12-22 DK DK18156034.3T patent/DK3342773T3/da active
- 2014-12-22 ME MEP-2018-85A patent/ME03001B/me unknown
- 2014-12-22 KR KR1020187034638A patent/KR102146477B1/ko active Active
- 2014-12-22 SI SI201431765T patent/SI3342773T1/sl unknown
- 2014-12-22 NZ NZ721175A patent/NZ721175A/en unknown
- 2014-12-22 CN CN201480070710.XA patent/CN105934434B/zh active Active
- 2014-12-22 LT LTEP14827669.4T patent/LT3087075T/lt unknown
- 2014-12-22 SM SM20180193T patent/SMT201800193T1/it unknown
- 2014-12-22 EA EA201891553A patent/EA201891553A1/ru unknown
- 2014-12-22 SI SI201430630T patent/SI3087075T1/en unknown
- 2014-12-22 AU AU2014370010A patent/AU2014370010B2/en active Active
- 2014-12-22 ES ES14827669.4T patent/ES2664799T3/es active Active
- 2014-12-22 SG SG11201604491VA patent/SG11201604491VA/en unknown
- 2014-12-22 PL PL14827669T patent/PL3087075T3/pl unknown
- 2014-12-22 UA UAA201606436A patent/UA118463C2/uk unknown
- 2014-12-22 EP EP14827669.4A patent/EP3087075B1/en active Active
- 2014-12-22 SG SG10201912586UA patent/SG10201912586UA/en unknown
- 2014-12-22 PH PH1/2016/501204A patent/PH12016501204B1/en unknown
- 2014-12-22 UA UAA201806052A patent/UA124667C2/uk unknown
- 2014-12-22 JP JP2016560876A patent/JP6243062B2/ja active Active
- 2014-12-22 MX MX2020000404A patent/MX392440B/es unknown
2015
- 2015-08-07 NO NO15766627A patent/NO3183247T3/no unknown
2016
- 2016-02-05 US US15/017,394 patent/US9968601B2/en active Active
- 2016-05-25 IL IL245846A patent/IL245846B/en active IP Right Grant
- 2016-06-15 DO DO2016000140A patent/DOP2016000140A/es unknown
- 2016-06-16 CL CL2016001537A patent/CL2016001537A1/es unknown
- 2016-06-16 SV SV2016005229A patent/SV2016005229A/es unknown
- 2016-06-17 GT GT201600123A patent/GT201600123A/es unknown
- 2016-06-23 CU CUP2016000097A patent/CU20160097A7/es unknown
2017
- 2017-09-08 JP JP2017172941A patent/JP6530792B2/ja active Active
- 2017-09-14 AU AU2017228612A patent/AU2017228612B2/en active Active
2018
- 2018-02-12 ZA ZA2018/00913A patent/ZA201800913B/en unknown
- 2018-03-19 HR HRP20180460TT patent/HRP20180460T1/hr unknown
- 2018-03-30 CY CY20181100354T patent/CY1120104T1/el unknown
- 2018-04-04 US US15/945,685 patent/US10342794B2/en active Active
- 2018-08-27 HK HK18111002.3A patent/HK1251563A1/zh unknown
2019
- 2019-05-15 US US16/413,458 patent/US10828299B2/en active Active
- 2019-05-17 JP JP2019093810A patent/JP2019172680A/ja active Pending
- 2019-09-26 AU AU2019236696A patent/AU2019236696B2/en active Active
2020
- 2020-10-28 US US17/082,595 patent/US11517570B2/en active Active
2021
- 2021-02-11 HR HRP20210233TT patent/HRP20210233T1/hr unknown
2022
- 2022-11-18 US US18/057,195 patent/US12263163B2/en active Active

Also Published As

Publication number	Publication date
SMT201800193T1 (it)	2018-05-02
BR112016014643B1 (pt)	2022-10-25
HK1251563A1 (zh)	2019-02-01
MD20160078A2 (ro)	2017-01-31
MX2016008456A (es)	2017-01-11
PH12016501204A1 (en)	2016-08-15
MX2020000404A (es)	2022-05-17
AU2017228612B2 (en)	2019-06-27
CA2875877C (en)	2021-10-26
MX392440B (es)	2025-03-24
SG10201912586UA (en)	2020-02-27
HUE053815T2 (hu)	2021-07-28
PH12016501204B1 (en)	2023-04-26
SG11201604491VA (en)	2016-07-28
KR20200098735A (ko)	2020-08-20
EA201891553A1 (ru)	2019-04-30
US11517570B2 (en)	2022-12-06
CU20160097A7 (es)	2017-02-02
ME03001B (me)	2018-10-20
PL3087075T3 (pl)	2019-03-29
CN105934434B (zh)	2017-12-12
JP2018021063A (ja)	2018-02-08
US20160310490A1 (en)	2016-10-27
CN107746405A (zh)	2018-03-02
CY1120104T1 (el)	2018-12-12
SV2016005229A (es)	2017-07-28
DK3342773T3 (da)	2021-02-15
DOP2016000140A (es)	2016-06-30
JP6243062B2 (ja)	2017-12-06
HRP20210233T1 (hr)	2021-04-02
UA118463C2 (uk)	2019-01-25
EP3342773B1 (en)	2020-11-11
KR20180130598A (ko)	2018-12-07
TWI662037B (zh)	2019-06-11
TW201609735A (zh)	2016-03-16
AU2014370010B2 (en)	2017-07-06
GT201600123A (es)	2017-12-01
SI3342773T1 (sl)	2021-04-30
US20180325896A1 (en)	2018-11-15
KR102146477B1 (ko)	2020-08-21
KR20160102041A (ko)	2016-08-26
SI3087075T1 (en)	2018-06-29
MD4666C1 (ro)	2021-01-31
KR101925859B1 (ko)	2018-12-07
PE20160995A1 (es)	2016-10-23
PH12020551986A1 (en)	2023-12-11
AU2019236696B2 (en)	2021-07-15
NZ721175A (en)	2017-05-26
MD4666B1 (ro)	2019-12-31
IL245846A0 (en)	2016-08-02
ES2851335T3 (es)	2021-09-06
JP6530792B2 (ja)	2019-06-12
WO2015100217A1 (en)	2015-07-02
US10828299B2 (en)	2020-11-10
US12263163B2 (en)	2025-04-01
UY35898A (es)	2015-07-31
AP2016009274A0 (en)	2016-06-30
MX371024B (es)	2020-01-13
DK3087075T3 (en)	2018-03-19
ZA201800913B (en)	2022-07-27
PT3087075T (pt)	2018-04-09
CR20160287A (es)	2016-09-19
EP3087075B1 (en)	2018-02-14
CA2875877A1 (en)	2015-06-23
US20210060011A1 (en)	2021-03-04
US9968601B2 (en)	2018-05-15
TW201940488A (zh)	2019-10-16
MY199564A (en)	2023-11-07
RS57182B1 (sr)	2018-07-31
EP3342773B9 (en)	2021-06-09
US20190388419A1 (en)	2019-12-26
EP3087075A1 (en)	2016-11-02
UA124667C2 (uk)	2021-10-27
PL3342773T3 (pl)	2021-06-14
US10342794B2 (en)	2019-07-09
EA031131B1 (ru)	2018-11-30
EP3342773A1 (en)	2018-07-04
NO3183247T3 (pt)	2018-04-28
HUE037662T2 (hu)	2018-09-28
LT3087075T (lt)	2018-04-10
ES2664799T3 (es)	2018-04-23
HRP20180460T1 (hr)	2018-06-01
JP2017501229A (ja)	2017-01-12
AU2017228612A1 (en)	2017-10-05
SG10201707432SA (en)	2017-10-30
CN107746405B (zh)	2020-09-22
US20230158023A1 (en)	2023-05-25
IL245846B (en)	2018-10-31
CL2016001537A1 (es)	2016-12-02
AR098912A1 (es)	2016-06-22
AU2019236696A1 (en)	2019-10-17
BR112016014643A2 (pt)	2017-08-08
HK1256999A1 (en)	2019-10-11
JP2019172680A (ja)	2019-10-10
TWI735853B (zh)	2021-08-11
CN105934434A (zh)	2016-09-07
EA201690989A1 (ru)	2016-11-30
AU2014370010A1 (en)	2016-06-30

Publication	Publication Date	Title
HRP20180460T1 (hr)	2018-06-01	Inhibitori syk
IL243578A0 (en)	2016-02-29	syk inhibitors
EP2970340A4 (en)	2016-10-19	BETA-Lactamase INHIBITORS
GB201413149D0 (en)	2014-09-10	No details
EP2943204A4 (en)	2016-11-09	BETA-Lactamase INHIBITORS
ZA201506156B (en)	2017-11-29	Novel inhibitors
GB201314578D0 (en)	2013-09-25	Bicyclic inhibitors
GB201317609D0 (en)	2013-11-20	Inhibitor compounds
GB201410903D0 (en)	2014-08-06	No details
GB201421649D0 (en)	2015-01-21	No details
GB201418212D0 (en)	2014-11-26	No details
GB201421548D0 (en)	2015-01-21	No details
GB201418129D0 (en)	2014-11-26	No details
GB201408089D0 (en)	2014-06-18	No details
GB201418214D0 (en)	2014-11-26	No details
GB201416327D0 (en)	2014-10-29	No details
GB201407200D0 (en)	2014-06-11	No details
GB201417843D0 (en)	2014-11-26	No details
GB201420520D0 (en)	2014-12-31	No details
GB201500998D0 (en)	2015-03-04	No details
HK1225374A1 (en)	2017-09-08	Syk inhibitors
GB201305503D0 (en)	2013-05-08	Inhibitor
GB201420267D0 (en)	2014-12-31	No details
GB201321328D0 (en)	2014-01-15	Inhibitor compounds
GB201323054D0 (en)	2014-02-12	No details